Vinorelbine For Treatment of Advanced Non-Small-Cell Lung Cancer
Vinorelbine (Navelbine - Burroughs Wellcome), a semisynthetic vinca alkaloid, has been approved by the US Food and Drug Administration for parenteral use in the treatment of advanced non-small-cell lung cancer (NSCLC). Various combinations of cisplatin (Platinol), vinblastine (Velban, and others), mitomycin (Mutamycin), ifosfamide (Ifex), etoposide (VePesid) and paclitaxel (Taxol) have been used previously for this indication....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Vinorelbine For Treatment of Advanced Non-Small-Cell Lung Cancer
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 955
Article Code: 955b
Date: August 18, 1995
Volume: 37
Pages: 72-73
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 955
Article Code: 955b
Date: August 18, 1995
Volume: 37
Pages: 72-73
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)